Funding for this research was provided by:
National Institute of General Medical Sciences (R35GM130119)
Cancer Prevention and Research Institute of Texas (RR160032)
University of Texas MD Anderson Cancer Center (P30 CA016672)
Article History
Received: 13 May 2020
Accepted: 30 September 2020
First Online: 15 October 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: MM is a shareholder in Pionyr Immunotherapeutics. TH is a consultant for Repare Therapeutics. The remaining authors declare no competing interests.